Notable Insider Report: Why Kristin Peck Sold 10,092 Shares of Zoetis Inc (NYSE:ZTS)?

November 23, 2016 - By Richard Conner

Notable Insider Report: Why Kristin Peck Sold 10,092 Shares of Zoetis Inc (NYSE:ZTS)?

Kristin Peck Insider Sell

Kristin Peck, the Executive Vice President of Zoetis Inc, unloaded 10,092 shares of the company, valued at $500,059 U.S. Dollars, totalled based on $49.6 for a share. Currently, Mr. Kristin, holds 22,768 shares, which accounts for 0.00% of the company’s market capitalization. The date of deal was 23-11-2016, and it was disclosed in a SEC-filed Form 4, which you can see here.

Zoetis Inc (NYSE:ZTS) Ratings Coverage

Out of 11 analysts covering Zoetis Inc (NYSE:ZTS), 8 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 73% are positive. $58 is the highest target while $48 is the lowest. The $53.50 average target is 6.70% above today’s ($50.14) stock price. Zoetis Inc has been the topic of 20 analyst reports since July 24, 2015 according to StockzIntelligence Inc. As per Thursday, August 6, the company rating was upgraded by William Blair. The stock of Zoetis Inc (NYSE:ZTS) earned “Outperform” rating by Credit Suisse on Thursday, February 4. The stock has “Sell” rating given by Goldman Sachs on Friday, May 6. The firm has “Buy” rating by Bank of America given on Thursday, September 29. The rating was upgraded by Zacks on Thursday, September 17 to “Buy”. The stock of Zoetis Inc (NYSE:ZTS) has “Outperform” rating given on Friday, September 11 by BMO Capital Markets. The rating was maintained by Jefferies on Tuesday, March 15 with “Buy”. The company was maintained on Tuesday, June 14 by Jefferies. The stock of Zoetis Inc (NYSE:ZTS) earned “Hold” rating by Zacks on Monday, September 7. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, June 1.

Insitutional Activity: The institutional sentiment increased to 1.19 in 2016 Q2. Its up 0.11, from 1.08 in 2016Q1. The ratio improved, as 48 funds sold all Zoetis Inc shares owned while 212 reduced positions. 72 funds bought stakes while 210 increased positions. They now own 451.82 million shares or 1.32% less from 457.84 million shares in 2016Q1.

Harvest Mgmt Ltd Liability holds 0.18% or 5,000 shares in its portfolio. Creative Planning accumulated 0% or 5,431 shares. State Of Wisconsin Invest Board has 0.05% invested in the company for 277,350 shares. Greystone Managed Invs Inc accumulated 157,890 shares or 0.31% of the stock. The New York-based Gilder Gagnon Howe Company Llc has invested 0.01% in Zoetis Inc (NYSE:ZTS). Berkshire Asset Mngmt Limited Liability Corp Pa holds 27,140 shares or 0.2% of its portfolio. Bancorporation accumulated 0.07% or 87,274 shares. The Pennsylvania-based Baldwin Investment Lc has invested 0.62% in Zoetis Inc (NYSE:ZTS). Hl Finance Services Limited Company holds 0.03% of its portfolio in Zoetis Inc (NYSE:ZTS) for 24,039 shares. Harvest Cap Strategies Ltd Liability Corp has invested 1.07% of its portfolio in Zoetis Inc (NYSE:ZTS). Meyer Handelman accumulated 0.02% or 9,500 shares. Macquarie Grp Inc Ltd holds 0.01% or 90,200 shares in its portfolio. Guggenheim Cap Limited Liability Company has 0.15% invested in the company for 987,872 shares. Moreover, 1St Source Bancorp has 0.03% invested in Zoetis Inc (NYSE:ZTS) for 4,823 shares. Autus Asset reported 98,229 shares or 1.06% of all its holdings.

Insider Transactions: Since September 1, 2016, the stock had 1 buy, and 3 sales for $2.74 million net activity. 9,797 shares with value of $494,063 were sold by Lagano Roxanne on Tuesday, November 8. The insider MCCALLISTER MICHAEL B bought $102,680. Another trade for 32,097 shares valued at $1.64M was made by Chen Heidi C. on Thursday, September 1. Another trade for 13,870 shares valued at $710,838 was made by Fenton Andrew on Friday, September 2.

About 2.06 million shares traded hands. Zoetis Inc (NYSE:ZTS) has risen 2.46% since April 21, 2016 and is uptrending. It has underperformed by 2.87% the S&P500.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company has a market cap of $24.60 billion. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish , and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It has a 36.32 P/E ratio. It operates through two divisions: the United States and International.

According to Zacks Investment Research, “Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.”

Analysts await Zoetis Inc (NYSE:ZTS) to report earnings on February, 21. They expect $0.46 EPS, up 6.98% or $0.03 from last year’s $0.43 per share. ZTS’s profit will be $225.69M for 27.25 P/E if the $0.46 EPS becomes a reality. After $0.52 actual EPS reported by Zoetis Inc for the previous quarter, Wall Street now forecasts -11.54% negative EPS growth.

ZTS Company Profile

Zoetis Inc., incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Firm operates through two divisions: the United States and International. Within each of these divisions, the Company offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>